Published in Liver Transpl on May 01, 2008
Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care (2012) 1.30
Impact of MELD-based allocation on end-stage renal disease after liver transplantation. Am J Transplant (2011) 1.17
Renal dysfunction in chronic liver disease. Crit Care (2010) 1.03
Short-term pretransplant renal replacement therapy and renal nonrecovery after liver transplantation alone. Clin J Am Soc Nephrol (2013) 0.99
Renal outcomes of simultaneous liver-kidney transplantation compared to liver transplant alone for candidates with renal dysfunction. Clin Transplant (2014) 0.81
Predictors of renal recovery in patients with pre-orthotopic liver transplant (OLT) renal dysfunction. BMC Nephrol (2013) 0.81
Pre-transplant kidney function predicts chronic kidney disease after liver transplant: meta-analysis of observational studies. Dig Dis Sci (2011) 0.80
Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int (2008) 0.79
Chronic Kidney Disease and Related Long-Term Complications After Liver Transplantation. Adv Chronic Kidney Dis (2015) 0.77
End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease. Clin Transplant (2014) 0.75
Transplantation: impact of pretransplant renal insufficiency. Liver Transpl (2008) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med (2013) 7.40
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95
Informing candidates for solid-organ transplantation about donor risk factors. N Engl J Med (2008) 2.83
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications. Transplantation (2003) 2.63
Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 2.57
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation (2010) 2.20
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87
The North American Study for the Treatment of Refractory Ascites. Gastroenterology (2003) 1.87
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf (2011) 1.76
Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology (2012) 1.74
Creating a medical, ethical, and legal framework for complex living kidney donors. Clin J Am Soc Nephrol (2006) 1.74
Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl (2006) 1.72
Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl (2008) 1.72
Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2004) 1.68
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 1.61
Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality. J Am Soc Nephrol (2006) 1.57
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int (2008) 1.56
Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl (2010) 1.56
Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis. Liver Transpl (2013) 1.52
Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology (2006) 1.50
Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci (2007) 1.50
Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology (2004) 1.49
Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol (2007) 1.49
Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J Heart Lung Transplant (2005) 1.46
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol (2002) 1.43
Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2009) 1.41
Ascites after liver transplantation--a mystery. Liver Transpl (2004) 1.40
Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era. Liver Transpl (2011) 1.37
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol (2009) 1.37
New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology (2013) 1.35
Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis (2008) 1.33
Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease? Clin J Am Soc Nephrol (2006) 1.33
Serum apoptosis markers in acute liver failure: a pilot study. Clin Gastroenterol Hepatol (2007) 1.29
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology (2007) 1.27
Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol (2008) 1.26
Biliary casts after orthotopic liver transplantation: clinical factors, treatment, biochemical analysis. Am J Gastroenterol (2003) 1.23
Interleukin-6 from intrahepatic cells of bone marrow origin is required for normal murine liver regeneration. Hepatology (2002) 1.23
Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf (2013) 1.23
Allograft survival following adult-to-adult living donor liver transplantation. Am J Transplant (2004) 1.20
Portal vein thrombosis: a concise review. Am J Gastroenterol (2002) 1.20
Current trends in living donor liver transplantation for primary sclerosing cholangitis. Transplantation (2011) 1.19
Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA. Liver Transpl (2004) 1.19
Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci (2012) 1.18
A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes (2010) 1.18
Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer (2010) 1.18
Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology (2014) 1.16
Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg (2010) 1.13
Successful aspiration and ethanol sclerosis of a large, symptomatic, simple liver cyst: case presentation and review of the literature. World J Gastroenterol (2006) 1.12
Superior survival using living donors and donor-recipient matching using a novel living donor risk index. Hepatology (2014) 1.12
A multicenter evaluation of safety of early extubation in liver transplant recipients. Liver Transpl (2007) 1.10